Key terms
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SRPT news
Apr 08
10:00pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Apr 04
7:46pm ET
Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential
Mar 22
7:56am ET
Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Mar 13
5:45am ET
Sarepta Therapeutics: A Strong Buy on Promising Drug Outlook and Strategic Growth Potential
Mar 13
2:35am ET
Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships
Mar 07
8:17am ET
PepGen price target lowered to $20 from $21 at Wedbush
Mar 06
7:26am ET
Sarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging Competitors
Mar 06
6:31am ET
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy bio (TSVT)
Mar 01
7:48am ET
Sarepta Therapeutics (SRPT) Gets a Hold from Oppenheimer
Mar 01
7:19am ET
Sarepta price target raised to $167 from $164 at UBS
Mar 01
1:31am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT)
Mar 01
1:12am ET
Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Advancements
Mar 01
12:55am ET
Buy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising Outlook
Feb 29
8:29am ET
Sarepta price target raised to $157 from $151 at RBC Capital
Feb 29
7:31am ET
Analysts Are Bullish on These Healthcare Stocks: Addus Homecare (ADUS), Jazz Pharmaceuticals (JAZZ)
Feb 29
7:25am ET
Sarepta Therapeutics: A Strong Buy on Robust Financials and Elevidys’ Market Success
Feb 29
6:55am ET
Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Drug Pipeline Prospects
Feb 29
6:18am ET
Sarepta price target raised to $172 from $160 at Citi
Feb 29
6:12am ET
Sarepta price target raised to $185 from $141 at Barclays
Feb 29
5:50am ET
Analysts’ Top Healthcare Picks: Amgen (AMGN), Sarepta Therapeutics (SRPT)
Feb 29
5:30am ET
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR)
Feb 28
10:10pm ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Immunocore Holdings (IMCR)
Feb 28
4:29pm ET
Sarepta reports Q4 EPS 82c, consensus 1c
Feb 20
7:40am ET
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT)
Feb 20
7:15am ET
Sarepta price target raised to $165 from $135 at TD Cowen
Feb 20
7:00am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF) and Sarepta Therapeutics (SRPT)
Feb 19
6:35pm ET
Sarepta Therapeutics’ Stock Buy Rating Affirmed Amid Positive FDA Regulatory Milestones
Feb 16
5:45pm ET
Buy Rating on Sarepta Therapeutics Amid Favorable FDA Review and Potential Broadening of Elevidys’ Label
Feb 16
5:36pm ET
Buy Rating Affirmed for Sarepta Therapeutics Amid Anticipated Elevidys Label Expansion and Market Growth Potential
Feb 16
5:35pm ET
Sarepta Therapeutics: Strong Buy on Regulatory Tailwinds and Expanding Market Potential for Elevidys
Feb 16
5:20pm ET
Sarepta price target raised to $169 from $164 at BofA
No recent press releases are available for SRPT
SRPT Financials
Key terms
Ad Feedback
SRPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SRPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range